Media Details

  • Home
  • Media
  • Details
  2020-11-18 21:32:40

Commencement Of Pivotal Phase IV Clinical Study: The Team Behind The Scene

- The Company Has Lined Up A Strong Team To Support The Study

KUALA LUMPUR, 18 NOVEMBER 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code:9601) has begun its Phase IV clinical study on COVID-19 vaccine with E-MO Biology Inc (“EBI”) whose key business revolves around biology research and development activities besides indicating booster polio vaccine can reduce COVID-19 SARS-COV-2 infection and severity.
The Phase IV clinical study will be led by EBI founder and managing director, Dr. Xie Qiyi (“Dr. Xie”).